| PICO | Description |
|---|---|
| Population | Patients with obesity-related heart failure with preserved ejection fraction (HFpEF), enrolled in the STEP-HFpEF program, involving 1,145 participants aged ≥18 years. |
| Intervention | Once-weekly semaglutide 2.4 mg administered for 52 weeks, aimed at improving New York Heart Association (NYHA) functional class, HF symptoms, and reducing bodyweight and inflammation markers. |
| Comparison | Placebo treatment provided under double-blind, randomized conditions for the same duration (52 weeks), across consistent baseline NYHA functional class categories. |
| Outcome | Semaglutide significantly improved NYHA functional class compared to placebo, with 32.6% of patients improving and fewer experiencing deterioration. Also, semaglutide improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores and physical function, but similar body weight reduction (-8.4% to -8.3%), and showed consistent improvements in biomarkers across NYHA classes. |
Source: Schou, Morten, et al. “Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.” J Am Coll Cardiol, 2024 Jul 16; 84(3):247-257. Read article here.
